ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can't
If a record IPO wasn’t enough to put RemeGen on the map, perhaps a deal with Seagen — sporting $200 million in cash — might.
At the center of the licensing pact is disitamab vedotin, an anti-HER2 antibody-drug conjugate that will slide directly into Seagen’s pipeline, except in certain Asian countries where China-based RemeGen will be keeping development and commercialization rights.
The fellow ADC specialists have been following each other for quite a while, RemeGen CEO Jianmin Fang tells me, as his trans-Pacific team leveraged Seagen’s linker technology and kept it posted on clinical data. It just happens to be the right time to pull the trigger.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
